ArticleTranslational cancer research2020
Effect of node status on breast cancer survival by subtype: a single-center retrospective cohort study.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Breast Cancer Presentation, Treatment Patterns, and Progression-Free Survival at a Tertiary Oncology Centre in Bangladesh: A Retrospective Study.Cancer reports (Hoboken, N.J.) · 2026Observational
- MRI-Based Radiomics Model for Classifying Axillary Lymph Node Burden and Disease-Free Survival in Patients With Early-Stage Breast Cancer.Journal of magnetic resonance imaging : JMRI · 2026Article
- Dual Anti-HER2 Therapy Vs Trastuzumab Alone with Neoadjuvant Anthracycline and Taxane in HER2-Positive Early-Stage Breast Cancer: Real-World Insights.Biologics : targets & therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNodal involvement and molecular subtypes were used as independent prognostic indicators in women with breast cancer. However, they did not adequately address the effect of node status by subtype in outcomes.
methodsWe performed a retrospective review of data from 2004 to 2011 from the Affiliated Union Hospital of Fujian Medical University with newly diagnosed stage I to III breast cancer to investigate the relationship between node status and 5-year disease-free survival (DFS) and breast cancer-specific survival (BCSS) by molecular subtype. The Cox proportional hazards model was used for multivariate analysis.
resultsMedian follow-up time was 6.4 years. Luminal HER2 and luminal B were the subtypes with a higher percentage of nodal involvement and high-volume nodal involvement (≥4 positive lymph node) than luminal A. The effect of node status on the prognosis varied with molecular subtype. There was no difference in 5-year DFS and BCSS between stage N1 or N2 and N0 groups in patients with luminal A disease. Nodal involvement in women with the luminal B, luminal HER2, and triple-negative subtypes showed significant difference for 5-year DFS and BCSS compared to the node negative group.
conclusionsNodal involvement seems to be associated with worse survival in women with the luminal B, luminal HER2, and triple-negative subtypes, but not with the luminal A subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.